1 July 2022 - Vitrakvi (larotrectinib) will list for the first time for the treatment of adult and paediatric patients with certain types of locally advanced or metastatic solid tumours harbouring specific gene fusions. 

An average of 60 patients per year could benefit from this listing. Without subsidy, patients may pay over $308,000 per course of treatment.

The PBS listing of Brukinsa (zanubrutinib) will be expanded to include the treatment of Waldenström's macroglobulinaemia, an uncommon type of blood cancer.

Read Minister of Health press release